Effect of renal impairment on pharmacodynamics and pharmacokinetics of RO4998452: A multiple-center, open-label, parallel group study following single oral dosing of RO4998452 to Type 2 Diabetes patients with varying degrees of renal impairment.
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2016
At a glance
- Drugs Tofogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Roche
- 15 Sep 2010 Status changed from active, no longer recruiting to completed as reported by Roche.
- 25 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by Roche record.
- 18 Feb 2010 Planned number of patients changed from 32 to 36 as reported by ClinicalTrials.gov.